Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L. Hauser SL, et al. Among authors: kappos l. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(2):e200094. doi: 10.1212/NXI.0000000000200094. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36792367 Free PMC article. Clinical Trial.
Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Among authors: kappos l. Neurology. 2008 Sep 2;71(10):766-73. doi: 10.1212/01.wnl.0000320512.21919.d2. Neurology. 2008. PMID: 18765653 Review.
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.
Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Baranzini SE, et al. Among authors: kappos l. Hum Mol Genet. 2009 Feb 15;18(4):767-78. doi: 10.1093/hmg/ddn388. Epub 2008 Nov 14. Hum Mol Genet. 2009. PMID: 19010793 Free PMC article.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, Wu W, Uitdehaag BM, Kappos L; GeneMSA Consortium; Polman CH, Matthews PM, Hauser SL, Gibson RA, Oksenberg JR, Barnes MR. Baranzini SE, et al. Among authors: kappos l. Hum Mol Genet. 2009 Jun 1;18(11):2078-90. doi: 10.1093/hmg/ddp120. Epub 2009 Mar 13. Hum Mol Genet. 2009. PMID: 19286671 Free PMC article.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data.
Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene); Chibnik LB, Hafler DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR. Wang JH, et al. Among authors: kappos l. Genome Med. 2011 Jan 18;3(1):3. doi: 10.1186/gm217. Genome Med. 2011. PMID: 21244703 Free PMC article.
794 results